EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Acquisition expands Merck’s growing hematology portfolio
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)